Plain-English translation of NCT06887088 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a two-step treatment plan using encorafenib plus binimetinib followed by cemiplimab and fianlimab for people with melanoma that has spread to the brain and is causing symptoms like headaches, seizures, or neurological problems. The first phase uses targeted oral medications designed to work against the specific genetic mutation found in your cancer. After about 8 weeks, you would switch to intravenous immunotherapy medications that help your immune system fight the cancer.
People with melanoma that has spread to the brain with symptoms have limited treatment options—current approaches either work poorly with symptoms present or stop working quickly. This trial is exploring whether combining targeted therapy first, followed by immunotherapy, might offer better and longer-lasting results than either approach alone.
You likely qualify if…
You likely don't qualify if…
If you enroll, you would first take two oral medications by mouth daily for about 8 weeks while being monitored with regular clinic visits and brain imaging. After stopping these medications, you would receive intravenous infusions of the second drug combination every 3 weeks for up to 2 years at a hospital or clinic. Throughout the trial, you would have regular blood tests, imaging scans, and appointments with your medical team to check how you're responding and watch for side effects.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
Spain